As of 11 August 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy. The HTA Council hereby releases its preliminary recommendation on the continue reading : HTA Council Preliminary Recommendation on trastuzumab 440 mg lyophilized powder for intravenous (IV) infusion for the treatment of HER-2 overexpressing early-stage breast cancer, taken alone or in combination with chemotherapy
HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
As of 14 July 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC). The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments continue reading : HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
As of 08 July 2026, the HTA Council has completed the evidence appraisal on the assessment of ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for the treatment of hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP) in adult hospitalized patients ≥18 years. As a continue reading : HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic continue reading : HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
As of 16 June 2026, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of levothyroxine sodium 12.5 micrograms (mcg) and 25mcg tablets for the management of hypothyroidism of any etiology. The HTA Council hereby releases its preliminary recommendation on the said health technology for stakeholder feedback and comments from continue reading : HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology